Belight builds on the regulation of melanin synthesis to the synergistic interaction between ingredients, particularly Grape seeds flavanol monomers (Vitis vinifera L. 100% from Champagne area), Licorice extract, Viniferin from grape pomace extract, Vitamin C. Research to date shows that the Belight formulation acts through its ability to inhibit the tyrosinase enzyme involved in melanin production, with an in-house in vitro study demonstrating an 85% reduction in tyrosinase activity.
A study conducted in France with 100 participants of Caucasian descent evaluated the effects of Belight at a daily dose of 300 mg over a 60-day period. The results were significant with 30% reduction in dark spots related to aging, 40% reduction in sun-induced pigmentation, 27% improvement in melasma (pregnancy mask) with visible improvements starting as early as 11 days after supplementation.
Another randomized, double-blind, placebo-controlled trial in Thailand involved 58 participants aged 45-65 with visible dark spots. After 12 weeks of taking 300 mg of Belight daily, the following results were observed- 24.5% improvement in overall skin brightness,76.8% reduction in dark spots. The trial utilized objective skin color assessments, reinforcing Belight’s efficacy in reducing hyperpigmentation. In addition to the above trials, Activ’Inside is set to release results from a clinical study conducted in Italy on Mediterranean skin types, expected in early 2025. Preliminary data suggests Belight’s efficacy in targeting hyperpigmentation across diverse skin tones, confirming its broad applicability and potential.
